These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37848970)

  • 1. Impact of COVID-19-related methadone regulatory flexibilities: views of state opioid treatment authorities and program staff.
    Mitchell SG; Jester J; Gryczynski J; Whitter M; Fuller D; Halsted C; Schwartz RP
    Addict Sci Clin Pract; 2023 Oct; 18(1):61. PubMed ID: 37848970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A trial of implementation facilitation to increase timely admission to methadone treatment.
    Gryczynski J; Mitchell SG; Whitter M; Fuller D; Mitchell MM; Edelman EJ; Schwartz RP
    J Subst Use Addict Treat; 2024 Jul; 162():209375. PubMed ID: 38642889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid treatment program culture and philosophy: Views of OTP staff and state officials on implementing interim methadone treatment.
    Burruss-Cousins K; Mitchell SG; Gryczynski J; Whitter M; Fuller D; Ibrahim A; Schwartz RP
    J Subst Use Addict Treat; 2024 Feb; 157():209265. PubMed ID: 38103832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. State guidance and system changes related to COVID-19: Impact on opioid treatment programs.
    Fuller DB; Gryczynski J; Schwartz RP; Halsted C; Mitchell SG; Whitter M
    J Subst Use Addict Treat; 2024 Mar; 158():209214. PubMed ID: 38042301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoption of methadone take home policy by U.S. state opioid treatment authorities during COVID-19.
    Roy V; Buonora M; Simon C; Dooling B; Joudrey P
    Int J Drug Policy; 2024 Feb; 124():104302. PubMed ID: 38183861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership.
    Levander XA; Pytell JD; Stoller KB; Korthuis PT; Chander G
    Subst Abus; 2022; 43(1):633-639. PubMed ID: 34666636
    [No Abstract]   [Full Text] [Related]  

  • 7. Loss, liberation, and agency: Patient experiences of methadone treatment at opioid treatment programs during the COVID-19 pandemic.
    López-Castro T; Jakubowski A; Masyukova M; Peterson M; Pierz A; Kodali S; Arnsten JH; Starrels JL; Nahvi S
    J Subst Use Addict Treat; 2024 Feb; 157():209235. PubMed ID: 38061636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Get in and get out, get on with life": Patient and provider perspectives on methadone van implementation for opioid use disorder treatment.
    Suen LW; Steiger S; Shapiro B; Castellanos S; Joshi N; Lambdin BH; Knight KR
    Int J Drug Policy; 2023 Nov; 121():104214. PubMed ID: 37778132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19.
    Brothers S; Viera A; Heimer R
    J Subst Abuse Treat; 2021 Dec; 131():108449. PubMed ID: 34098303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysis.
    Levander XA; Hoffman KA; McIlveen JW; McCarty D; Terashima JP; Korthuis PT
    Addict Sci Clin Pract; 2021 Dec; 16(1):72. PubMed ID: 34895346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "The idea is to help people achieve greater success and liberty": A qualitative study of expanded methadone take-home access in opioid use disorder treatment.
    Suen LW; Castellanos S; Joshi N; Satterwhite S; Knight KR
    Subst Abus; 2022; 43(1):1143-1150. PubMed ID: 35499469
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacy-based methadone treatment in the US: views of pharmacists and opioid treatment program staff.
    Wu LT; Mannelli P; John WS; Anderson A; Schwartz RP
    Subst Abuse Treat Prev Policy; 2023 Sep; 18(1):55. PubMed ID: 37697326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Sign Me Up": a qualitative study of video observed therapy (VOT) for patients receiving expedited methadone take-homes during the COVID-19 pandemic.
    Darnton JB; Bhatraju EP; Beima-Sofie K; Michaels A; Hallgren KA; Soth S; Grekin P; Woolworth S; Tsui JI
    Addict Sci Clin Pract; 2023 Mar; 18(1):21. PubMed ID: 36991506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nothing really changed: Arizona patient experience of methadone and buprenorphine access during COVID.
    Meyerson BE; Bentele KG; Russell DM; Brady BR; Downer M; Garcia RC; Garnett I; Lutz R; Mahoney A; Samorano S; Arredondo C; Andres HJ; Coles H; Granillo B
    PLoS One; 2022; 17(10):e0274094. PubMed ID: 36282806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acceptability, feasibility, and outcomes of a clinical pilot program for video observation of methadone take-home dosing during the COVID-19 pandemic.
    Hallgren KA; Darnton J; Soth S; Blalock KL; Michaels A; Grekin P; Saxon AJ; Woolworth S; Tsui JI
    J Subst Abuse Treat; 2022 Dec; 143():108896. PubMed ID: 36215911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic changes in methadone utilisation for opioid use disorder treatment: a retrospective observational study during the COVID-19 pandemic.
    Kennalley AL; Fanelli JL; Furst JA; Mynarski NJ; Jarvis MA; Nichols SD; McCall KL; Piper BJ
    BMJ Open; 2023 Nov; 13(11):e074845. PubMed ID: 37973543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shifting Medication Treatment Practices in the COVID-19 Pandemic: A Statewide Survey of Pennsylvania Opioid Treatment Programs.
    Krawczyk N; Maniates H; Hulsey E; Smith JS; DiDomenico E; Stuart EA; Saloner B; Bandara S
    J Addict Med; 2022 Nov-Dec 01; 16(6):645-652. PubMed ID: 35165225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient experiences of COVID-19-induced changes to methadone treatment in a large community-based opioid treatment program in Baltimore.
    Abidogun TM; Cole TO; Massey E; Kleinman M; Greenblatt AD; Seitz-Brown CJ; Magidson JF; Belcher AM
    J Subst Use Addict Treat; 2023 Feb; 145():208946. PubMed ID: 36880915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical incidents in Colorado's opioid treatment programs: A comparison of the COVID-19 pandemic to previous years.
    Bortz C; Armistead I; Bonaguidi A; Coyle DT
    J Subst Use Addict Treat; 2024 Jun; 161():209342. PubMed ID: 38513975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis.
    Hoffman KA; Foot C; Levander XA; Cook R; Terashima JP; McIlveen JW; Korthuis PT; McCarty D
    J Subst Abuse Treat; 2022 Oct; 141():108801. PubMed ID: 35589443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.